The global synthetic biology market is expected to grow at noteworthy CAGR around 26.4 % throughout the forecast period and reach around US$ 14 billion by 2026.
Synthetic Biology is one of the breakthrough technology created by the human race in the field of chemistry, organics, computer science and engineering. It has a variety of applications in biofuels, industrial inzymes, the manufacturing of vaccines and antibodies, bio-based chemical products and life scientific study in synthetic biology. Since these smaller parts or devices have been used to integrate particular systems, synthetic biologists create such biological systems using key elements (genetic circuits, part of enzymes and metabolism), and understand their efficiency. New medicinal products are now produced using synthetic biology to tackle emerging health concerns at a cell, molecular and genetic level.
The report provides analysis of global Synthetic Biology market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
Strong applications are expected to drive the synthetic biology market across different end use sectors, including agriculture, industrial chemicals and healthcare. The growth of the sector will promote shifting trends in manufacturing towards materials derivative from natural crops such as rubber, essential oils, food flavors and fragrances. Increasing research efforts to design, redesign, generate and alter live organisms, genetic materials and biological systems through scientific, technological and technical cooperation, will provide fresh growth possibilities for industry members in the forecast period.
Increasing investments in research and development operations backed by government agencies will give companies across the market favorable prospects. According to the National Science Foundation, from 2008 to 2014, USD 820 million has been invested in the synthetic biology industry and estimate that it is one of the world's biggest shareholders. Similarly, in 2008-2016, the United Kingdom spent over USD 330 million to support growth in the sector. Improved access to renewable energy, and lower carbon footprint, such as an optimized manufacturing method, contribute to publicly financed Synthetic Biology projects globally.
Growing demand for biofuels will promote market growth due to a worldwide energy crisis, fossil fuel depletion and growing pollution. Recent progress in the field of synthetic biology has led to a fourth-generation manufacturing of biofuels, which are used as the feedstock to produce specially designed microorgas. Increased global per-capita consumption of energy is likely to propel synthetic biology apps across the energy industry due to the fast industrialization caused by rising global population.
The synthetical biology industry is also boosting increased concern about food security with increasing population, changing climate and environmental stress. Synthetic biology seeks to achieve viable farming methods that enable the minimum use for enhanced yields of chemical fertilizers and pesticides. Increasing and tailored dietary or medicinal value, for example, for food production with better shelf life will promote apps for synthetic biology across the food and farming industries. Biosafety, biosecurity and the ethical risk of synthetic biology can, however, hamper the development of company.
The CAGR of core products should be more than 25% by 2026. Strong apps in the pharmaceutical sector support strong perspectives for synthetic genes, synthetic DNA sections, chassis organisms and synthetic cells and diagnostic fields. A wide variety of apps will increase demand for the world market, such as the manufacture of medicines, fuel and raw material for industrial procedures and food production. The positive perspective for the use of synthetically designed microbes in bioremediation will encourage development in the sector, such as break down of petroleum products into less toxic by-products, degradation of chemicals such as pesticides, dioxins, radioactive and pharmaceutical substances.
More than 19% of the market share in 2018 was represented by microfluidics. The need for an easy-to-use and cheap clinical diagnosis supporting the segment's growth has been increased. The main variables that can drive microfluid technology demand are rapid sampling / identification skills and reliable measures of the metabolic limitations of a man with minimum invasion. The rapid development of the global market in clinical diagnostics will also offer profitable company possibilities for players in the sector of synthetic biology.
Genetic engineering is expected to see significant increases over the timeframe envisaged. Increased technological advances in line with genetic engineering methods that are as effective as the standard therapys that drive this section of development in genetic disease therapy. CRISPR-Cas9 technologies are, for example, lately developed in the field of genetically-modifying plant strains and yeast in biofuels, because they are more precise, cheaper and more effective than the current techniques.
CAGR is anticipated to be registered by 24 per cent by 2026 on the agricultural synthetic biology market. This segment is likely to be supported by the increasing requirement to enhance output by changing the genetic sequence of plants, also called transgenic or GM plants. Increasing production of transgenic plants due to increased food demand, increasing population and favourable public policies stimulates market growth. The industry's expansion may however not be impeded by lower customer acceptance as a result of worries about GM crops, and by stringent legislation on manufacturing and product labeling.
In 2018 the applications for pharmaceuticals and diagnostics represented a market share of more than 75 percent. Increase adoption of biopharmaceutical microfluid technology to monitor and optimize the manufacturing of protein drugs fosteres general size of the market. Key benefits, including shorter analytical time, increased test parameter control, high resolution and molecular detection and separation sensitivities, and the cost reduction in fuel consumption rate for the microfluidics technology. Substantial demand for blood transport, chemical kinetics observation and drug-resistant antibiotic bacteria in nanoparticle research applications will promote the development of the industry in the near future.
It is anticipated that Europe will record the fastest possible CAGR over 24% by 2026. Increased R&D spending in medical and pharmaceutical businesses will promote the development of the region's synthetic biology industry. In-depth public study programs for sustainable renewable energy production and their application to food, feedingstuff, equipment, fibers, chemicals and bioenergy through effective and / or innovative techniques fueling regional development, for example ERASynBio and Horizon 2020.
Around 26 percent of Asia Pacific's market share in synthetic biology was in 2018. Increased awareness of the growth of chronic diseases in developing economies such as India and China will boost the scale of the market. Increasing food manufacturing needs with elevated dietary value, improved shelf-life, and no damaging allergens are ready to promote applications in biotechnology. In addition, the manufacturing of feedstock using engineered micro-organisms has been increasing to improve the quality of feed products based on animals or plants that promote regional market growth for synthetic biology.
Global Synthetic Biology Market, By Product
Global Synthetic Biology Market, By Technology
Global Synthetic Biology Market, By Application
Global Synthetic Biology Market, By Geography
The market research study on “Synthetic Biology Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Synthetic Biology market segments with market dynamics and their impact. The report also covers basic technology development policies.
Key Players & Strategies
Due to the existence of big, regional and multinational players on the market the synthetic biology industry is of competitive nature. Amyris, Integrated DNA technologies, DSM, Evolva, Twist biosciences, Editas Medicine, Inc., GenScript, Novozyme, Pareto Biotechnologies, Blue heron, and Thermo Fischer Scientific were all key industry participants. The firms are adopting approaches such as R&D collaborations, fresh product launches and company expansion joint ventures. Novozymes announced in September 2018 the launch of Balancius, a fresh feed additive that increases the gut's health for broiler chickens. This allows farmers to generate 3% more food from the same feed quantity and move towards more viable manufacturing. This business approach increases the base of customers and reduces the effect on the food production environment.
Synthetic biology is one of the world's most promising and rapidly increasing technology. Applications in the medical, agricultural, nanotechnological and industrial fields are diverse. A powerful company outlook for industry actors engaged in synthetic biology will probably be supported by increasing financing from government and private organisations. The pace and effectiveness of DNA synthesis combined with increased genome information are the main drivers for the use of cutting-edge techniques to manufacture commercial goods, including proteins and renewable chemicals.
Synthetic Biology is one of the breakthrough technology created by the human race in the field of chemistry, organics, computer science and engineering.
The global synthetic biology market is projected to reach around US$ 14 billion by 2026.
The global synthetic biology market is poised to grow at noteworthy CAGR around 26.4 % throughout the forecast period.
The growth of the sector will promote shifting trends in manufacturing towards materials derivative from natural crops such as rubber, essential oils, food flavors and fragrances.
The CAGR of core products should be more than 25% by 2026.
CAGR is anticipated to be registered by 24% by 2026 on the agricultural synthetic biology market.
Amyris, Integrated DNA technologies, DSM, Evolva, Twist biosciences, Editas Medicine, Inc., GenScript, Novozyme, Pareto Biotechnologies, Blue heron, and Thermo Fischer Scientific were all key industry participants.